查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2018-2028年肿瘤学和免疫学流式细胞术市场 - 全球行业规模、份额、趋势、竞争、机会和预测，按类型、按技术、按产品、按应用、按最终用户、按地区细分
市场调查报告书
商品编码
1309225

2018-2028年肿瘤学和免疫学流式细胞术市场 - 全球行业规模、份额、趋势、竞争、机会和预测，按类型、按技术、按产品、按应用、按最终用户、按地区细分

Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Technology, By Offering, By Application, By End User, By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计在 2024-2028 年的预测期内，全球肿瘤学和免疫学流式细胞仪市场将以稳定的复合年增长率增长。这主要归因于流式细胞仪在研究活动中的应用范围不断扩大以及新一代流式细胞仪的开发。据世界卫生组织称，癌症是造成全球疾病负担和死亡率的主要原因之一，而癌症预防、诊断和治疗战略仍是全球努力的方向。肿瘤学和免疫学中的流式细胞术是指测量血液、骨髓或其他组织样本中的细胞数量、活细胞百分比和细胞的某些特征（如大小和形状），以及细胞表面是否存在肿瘤标志物（如抗原）的实验室程序。免疫肿瘤学（IO）是研究免疫系统的抗癌功能，以及开发提高免疫系统抗癌能力的治疗方法。然而，对新的肿瘤学和免疫学技术/工具的需求不断增加，这将进一步推动全球肿瘤学和免疫学流式细胞仪市场的增长。此外，技术的发展和努力寻找特异灵敏的工具来监测治疗期间和治疗后的免疫反应，预计也将在预测的几年内推动市场的增长。

癌症发病率上升

在全球范围内，癌症是最常见的死亡原因之一。全球癌症病例的增加可能是肿瘤分子诊断市场扩大的一个因素。根据美国癌症协会的数据，2021 年美国新增癌症病例 180 万例，死亡 60 万例。

由于恶性细胞的扩增，医学专家正在加大研发力度，以创造出有助于预防和治疗癌症的疗法和诊断服务。癌症免疫疗法正成为不同疾病阶段多种肿瘤类型的标准治疗方法，可提高生存率，减少疾病复发。据美国食品和药物管理局（FDA）称，目前正在开展多项成功实施免疫学和肿瘤学治疗的临床试验，以评估多种癌症类型的疗效，实施组合疗法，从机理上了解新药开发或确定临床反应的免疫预测因子。因此，它们的治疗和开发的疗法是推动全球肿瘤学和免疫学流式细胞仪市场增长的原因。

技术进步

更先进技术的发展包括质谱流式细胞仪、成像流式细胞仪、基因组流式细胞仪和光谱流式细胞仪，这些技术通过以更高的分辨率同时表征单细胞中更多的细胞参数，扩大了研究免疫反应的能力。据研究人员称，免疫系统可以靶向摧毁癌细胞；因此，基于免疫肿瘤学的疗法涵盖了增强癌症患者免疫反应的不同方法，包括激活效应细胞、接种肿瘤抗原疫苗、注射溶瘤病毒、阻断抑制途径或免疫抑制机制、使用采用性嵌合抗原受体T细胞疗法以及放大保护途径。

最新进展与产品上市

全球肿瘤学和免疫学流式细胞仪市场的增长得益于主要市场参与者的出现。例如，2022 年 6 月，Becton, Dickinson 公司在国际流式细胞仪促进会（ISAC）上推出了新的细胞分拣技术。2022 年 9 月，一家公司，即 Becton, Dickinson，推出了 BD Research Cloud，这是一种基于云的软件解决方案，旨在改善免疫学、病毒学、癌症和传染病监测等多个领域研究人员的流式细胞仪流程，以实现更高质量的实验和更快的理解时间。此外，2022 年 2 月，Becton, Dickinson 收购了 Cytognos, S.L.，扩大了其流式细胞仪产品组合，并获得了 Cytognos S.L. 约 80 名科学家和专业人员的专业知识。

可用定制

TechSci Research 可根据给定的市场数据，为公司的特定需求提供定制服务。报告可提供以下定制选项：

公司信息

  • 其他市场参与者（最多五家）的详细分析和概况。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 覆盖市场
    • 研究年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基准方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概述
  • 主要市场细分概述
  • 主要市场参与者概述
  • 主要地区/国家概述
  • 市场驱动因素、挑战和趋势概述

第4章：客户之声

第5章：全球肿瘤学和免疫学流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额与预测
    • 按类型（免疫学、肿瘤学）
    • 按技术（细胞流式细胞仪、珠基流式细胞仪）
    • 按产品（试剂、仪器和耗材软件）
    • 按应用（转化研究、临床研究）
    • 按最终用户（医院、诊断实验室和参考实验室、制药和生物技术公司、学术研究机构、合同研究组织及其他）
    • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
    • 按公司（2022 年）
  • 市场地图
    • 按类型
    • 按技术
    • 按产品
    • 按应用
    • 按最终用户
    • 按地区

第 6 章 : 北美肿瘤学和免疫学流式细胞仪市场展望

  • 市场规模与预测
    • 按价值
  • 市场份额与预测
    • 按类型
    • 按技术
    • 按产品
    • 按应用
    • 按最终用户
    • 按国家
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲肿瘤学和免疫学流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额与预测
    • 按类型
    • 按技术
    • 按产品
    • 按应用
    • 按最终用户
    • 按国家
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 意大利
    • 西班牙

第 8 章 : 亚太地区肿瘤学和免疫学流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额与预测
    • 按类型
    • 按技术
    • 按产品
    • 按应用
    • 按最终用户
    • 按国家
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚

第 9 章 : 南美肿瘤学和免疫学领域的流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额与预测
    • 按类型
    • 按技术
    • 按产品
    • 按应用
    • 按最终用户
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章 : 中东和非洲肿瘤学与免疫学流式细胞仪市场前景

  • 市场规模与预测
    • 按价值
  • 市场份额与预测
    • 按类型
    • 按技术
    • 按产品
    • 按应用
    • 按最终用户
    • 按国家
  • 中东和非洲：国家分析
    • 阿联酋 肿瘤学和免疫学中的流式细胞仪
    • 沙特阿拉伯 肿瘤学和免疫学中的流式细胞术
    • 南非 肿瘤学和免疫学中的流式细胞术
    • 土耳其 肿瘤学和免疫学中的流式细胞术
    • 埃及 肿瘤学和免疫学中的流式细胞术

第 11 章 ：市场动态

  • 驱动因素
    • 癌症发病率上升
    • 技术进步
    • 最新发展和产品上市
  • 挑战
    • 流式细胞仪产品成本高昂
    • 错误的抗体反应

第 12 章 ：市场趋势与发展

第 13 章 ：竞争格局

  • 业务概述
  • 产品供应
  • 近期发展
  • 财务状况（报告）
  • 主要人员
    • Danaher Corporation
    • Merck KGaA
    • Miltenyi Biotec
    • Neo-Genomics Laboratories, Inc.
    • Thermo Fisher Scientific Inc
    • Cell Signaling Technology, Inc
    • Becton, Dickinson and Company
    • Agilent Technologies, Inc.
    • DiaSorin S.p.A (Luminex Corporation)
    • OPKO Health, Inc.

第 14 章：战略建议

简介目录
Product Code: 15020

Global Flow Cytometry in Oncology and Immunology Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. This can be ascribed due to the expansion of flow cytometry's applicability in research activities and the development of next-generation flow cytometers. According to the World Health Organization, Cancer is one of the leading causes of disease burden and mortality in the world, and strategies for cancer prevention, diagnosis, and treatment are still a global effort. Flow cytometry in oncology and immunology refers to the laboratory procedure to measure the number of cells, the percentage of live cells, and certain characteristics of cells, such as size and shape, in a sample of blood, bone marrow, or other tissue, the presence of tumor markers, such as antigens, on the surface of the cells. Immuno-oncology (IO) is the study of the immune system's functionality against cancer and the development of treatments that improve the ability of the immune system to fight the disease. However, the demand for new oncology and immunologic techniques/tools is increasing, which is further expected to drive the growth of global flow cytometry in the oncology and immunology market. Additionally, the development of technology and efforts to find specific and sensitive tools to monitor immune responses during and after therapy is thereby expected to drive the growth of the market in the forecast years.

The growing prevalence of cancer cases, the technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. However, the high cost of products of flow cytometry equipment is expected to hamper the growth of flow cytometry in the oncology and immunology market in the forecast years.

Rising Prevalence of Cancer Cases

Globally, Cancer is one of the prevalent causes of death. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's expansion. In the United States of America in 2021, there were 1.8 million new cases and 0.6 million cancer deaths, according to the American Cancer Society.

Medical professionals are stepping up their research and development efforts to create therapies and diagnostic services as a result of the expansion of malignant cells to aid the prevention and treatment of cancer. Cancer immunotherapy is becoming the standard of care for multiple tumor types at diverse disease stages, providing better survival with reduced disease recurrences. According to Food and Drug Administration (FDA), multiple clinical trials with successful implementation of immunology and oncology treatments are being conducted to evaluate the efficacy of treatments of multiple cancer types, to implement combinatorial therapies, to gain mechanistic insight for new drug development or to identify immune predictors of clinical response. Therefore, their treatment and developed therapies are responsible for propelling the growth of global flow cytometry in the oncology and immunology market.

Advancement in Technology

The development of more advanced technologies includes mass cytometry, imaging flow cytometry, genomic cytometry, and spectral cytometry with an expanded ability to study immune responses by characterizing more cellular parameters simultaneously in single cells with higher resolution. According to the researchers, the immune system can target and destroy cancer cells; therefore, immune-oncology-based therapies cover different approaches to boost the immune response in cancer patients, that range from activation of effector cells, vaccination with tumor antigens, administration of oncolytic viruses, blockage of inhibitory pathways or immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell therapy, and to amplify the protective pathways.

Recent Developments & Product Launches

The growth of global flow cytometry in the oncology and immunology market is witnessed due to the presence of major market players. For instance, in June 2022, Becton, Dickinson, and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). In September 2022, a company, namely Becton, Dickinson, launched BD Research Cloud, a cloud-based software solution designed to improve the flow cytometry process for researchers working in a variety of fields, such as immunology, virology, cancer, and infectious disease monitoring, in order to enable higher-quality experiments with faster time to understand. Additionally, in February 2022, Becton, Dickinson acquired Cytognos, S.L. and expanded its flow cytometry portfolio, and gained the expertise of ~80 scientists and professionals at Cytognos S.L.

Market Segmentation

Global Flow Cytometry in Oncology and Immunology Market can be segmented by type, technology, offering, application, end user, region, and company. Based on type, the market can be segmented into immunology and oncology. Based on technology, the market is fragmented into cell-based flow cytometry and bead-based flow cytometry. Based on the offering, the market is segmented into reagents, instruments, and consumables software. Based on application, the market is fragmented into translational research and clinical research. Based on end users, the market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.

Company Profiles

Danaher Corporation, Merck KGaA, Miltenyi Biotec, Neo-Genomics Laboratories, Inc., Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Agilent Technologies, Inc., DiaSorin S.p.A (Luminex Corporation), OPKO Health, Inc., etc., are some of the key players operating in the global flow cytometry in the oncology and immunology market.

Report Scope

In this report, Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

  • Immunology
  • Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

  • Cell-based flow cytometry
  • Bead-based flow cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

  • Reagents
  • Instruments
  • Consumables software

Flow Cytometry in Oncology and Immunology Market, By Application:

  • Translational Research
  • Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Others

Flow Cytometry in Oncology and Immunology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Immunology, Oncology)
    • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
    • 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
    • 5.2.4. By Application (Translational Research, Clinical Research)
    • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Technology
    • 5.3.3. By Offering
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By Offering
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Offering
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Offering
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Offering
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By Offering
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Offering
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Offering
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Offering
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Offering
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Offering
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By Offering
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Offering
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Offering
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Offering
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Offering
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Offering
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Flow Cytometry in Oncology and Immunology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Offering
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Offering
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Offering
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Offering
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Offering
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Offering
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Offering
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Offering
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User
    • 10.3.4. Turkey Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Technology
        • 10.3.4.2.3. By Offering
        • 10.3.4.2.4. By Application
        • 10.3.4.2.5. By End User
    • 10.3.5. Egypt Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Technology
        • 10.3.5.2.3. By Offering
        • 10.3.5.2.4. By Application
        • 10.3.5.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Rising Prevalence of Cancer Cases
    • 11.1.2. Advancement in Technology
    • 11.1.3. Recent Developments & Product Launches
  • 11.2. Challenges
    • 11.2.1. High Cost of the Products of the Flow Cytometry Equipment
    • 11.2.2. False antibody responses

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Danaher Corporation
    • 13.5.2. Merck KGaA
    • 13.5.3. Miltenyi Biotec
    • 13.5.4. Neo-Genomics Laboratories, Inc.
    • 13.5.5. Thermo Fisher Scientific Inc
    • 13.5.6. Cell Signaling Technology, Inc
    • 13.5.7. Becton, Dickinson and Company
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. DiaSorin S.p.A (Luminex Corporation)
    • 13.5.10. OPKO Health, Inc.

14. Strategic Recommendations